Page last updated: 2024-09-03

imatinib mesylate and Endocarditis, Loeffler

imatinib mesylate has been researched along with Endocarditis, Loeffler in 250 studies

Research

Studies (250)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	145 (58.00)	29.6817
2010's	88 (35.20)	24.3611
2020's	17 (6.80)	2.80

Authors

Authors	Studies
Akuthota, P; Kovalszki, A; Kwon, N; Requena, G; Steinfeld, J; van den Bosch, J; Van Dyke, MK	1
Anshu, A; Das, R; Jamwal, M; Lad, D; Rathore, S; Sreedharanunni, S; Virk, H	1
Bekir, L; Braham, N; Ghariani, I; Hamzaoui, S; Mahmoud, O	1
Furukawa, F; Kitayama, S; Makino, T; Mizawa, M; Mori, S; Shimizu, T; Torai, R; Yoto, A	1
Alberti, S; Bellani, V; Bucelli, C; Cattaneo, D; Croci, GA; Iurlo, A; Maronese, CA	1
Khoury, P; Klion, AD; Kuang, FL; Wechsler, ME; Weller, PF	1
Cheung, K; Fay, K; Krigstein, M; Lukeis, R; Menzies, A; Parker, A	1
Cattaneo, D; Gianelli, U; Iurlo, A	1
Adam, M; Bröckelmann, PJ; Wienemann, H	1
Gajkowska-Kulik, J; Helbig, G; Lewandowski, K; Rodzaj, M; Seferyńska, I; Świderska, A	1
Ackermann, F; Étienne, N; Groh, M; Kahn, JE; Lefèvre, G	1
Botella-Estrada, R; de Unamuno-Bustos, B; Navarro-Mira, MÁ; Torres-Navarro, I	1
Chung, KF; Lai, K; Wang, C; Xie, J; Zhang, J; Zhang, Q; Zhang, X	1
Blum, S; Brouland, JP; Chalandon, Y; Comoli, P; Comte, D; Du Pasquier, R; Dunet, V; Livio, F; Opota, O; Spertini, O; Tirefort, Y	1
Chen, Y; Cheng, Z; Luo, Y; Peng, H; Wang, Y; Xu, Y; Zhang, G; Zhang, Y	1
Gong, SJ; Hong, MH; Kashif, A; Kim, G; Kim, IS; Lee, JS; Lee, MS; Lee, NR; Nam, AR; Seok, PR; Song, IC; Sung, KH; Yang, SJ	1
Cai, Y; Du, X; Fan, JC; Liu, HX; Wang, JX; You, WW	1
Chen, LYC; Dou, C; Williams, AK	1
Campos-Gazeau, F; Chalayer, E; De Broucker, T; Denier, C; Groh, M; Guidoux, C; Hamidou, M; Hunault, M; Kahn, JE; Lefèvre, G; Lyoubi, A; Meunier, R; Muron, T; Rohmer, J; Sène, D; Slama, B; Tennenbaum, J; Venditti, L	1
Barbetseas, J; Benetos, G; Bonou, M; Diamantopoulos, P; Giannakopoulou, N; Kapelios, CJ; Korkolopoulou, P; Moyssakis, I; Variami, E	1
Espinet, B; Gallardo, F; García-Martínez, P; Hernandez-Muñoz, M; Llistosella, E; Pujol, RM; Rodríguez-Rivera, M; Sitjas, D	1
Choi, CW; Kim, DS; Lee, S	1
Hatayama, M; Ikuta, K; Okumura, T; Shindo, M; Toki, Y; Torimoto, Y; Yamamoto, M	1
Helbig, G	2
Huang, G; Li, J; Qin, T; Qu, S; Wang, Q; Xiao, Z; Xu, Z; Zhang, Y	1
Ai, XF; Fang, LW; Hu, NB; Jia, YJ; Li, B; Liu, JQ; Pan, LJ; Qin, TJ; Qu, SQ; Ru, K; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y	1
Abecasis, J; Afonso, C; Gouveia, R; Strong, C; Trabulo, M	1
Besses, C; Curto-Barredo, L; Espinet, B; Hashimoto, T; Ishii, N; Mascaró, JM; Pujol, RM; Segura, S	1
Alves, P; Bota, S; Constantino, C; Maia, R	1
Alam, H; Nazir, L; Riaz, A	1
Qu, SQ; Sun, XJ; Wang, Y	1
Athanasiadou, F; Giannopoulos, A; Hatzipantelis, E; Keivanidou, A; Pana, Z; Papageorgiou, T	1
Lee, SR; Yhim, HY	1
Helbig, G; Kyrcz-Krzemień, S	1
Chopra, Y; Grover, AK; Ramzan, M; Yadav, SP	1
Beghini, A; Cassin, R; Cortelezzi, A; Ferla, V; Fracchiolla, NS; Gianelli, U; Gottardi, E; Iurlo, A; Spinelli, O	1
Demoulin, JB; Essaghir, A	1
Kovalszki, A; Weller, PF	1
Kanashima, H; Murakami, A; Nakao, T; Tamagawa, N; Ueda, H; Yamane, T; Yorifuji, T; Yoshida, M	1
Beghini, A; Cambiaghi, S; Cortelezzi, A; Gianelli, U; Intermesoli, T; Iurlo, A; Lazzaroni, F; Orofino, N; Rambaldi, A; Spinelli, O	1
Chandía, M; Torres C, D	1
Ding, K; Pan, J; Ren, X; Shen, Y; Wang, D; Zhang, Z	1
Ali, SM; Campregher, PV; Chalmers, ZR; Chmielecki, J; Elvin, JA; Erlich, R; Frampton, GM; Hermann, R; Miles, CR; Miller, VA; Ohgami, RS; Palma, NA; Ross, JS; Stephens, PJ; Vergilio, JA; Yelensky, R	1
Géraud, C; Goerdt, S; Marx, A; Peitsch, WK; Reiter, A; Ziegler, B	1
Klion, AD	1
Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E	1
Falchi, L; Verstovsek, S	1
Roufosse, F	1
Bailey, NG; Castle, VP; Mody, RJ; Weyand, AC; Wu, YM; Yanik, GA	1
Hebestreit, H; Kunzmann, S; Leu, T; Simon, HU	1
Katayama, N; Masuya, M; Matsui, T; Monma, F; Nobori, T; Ohishi, K; Sada, A; Shimokariya, Y; Sugimoto, Y	1
Helbig, G; Hus, M; Kyrcz-Krzemień, S; Soja, A; Świderska, A	1
Feng, S; Han, M; He, Y; Liu, Q; Shi, Y; Yang, D; Zhang, R	1
Fassnacht, F; Fouret, P; Kahn, JE; Lefevre, G; Levy, V; Roumier, M; Russel, S; Varnous, S	1
Altamura, HK; Branford, S; Feng, J; Geoghegan, J; Hahn, CN; Holloway, MR; Moore, S; Nicola, M; Ross, DM; Schreiber, AW; Scott, HS; Yeoman, AL	1
Hayakawa, K; Komatsu, T; Tanimoto, T; Tsuda, K	1
Arthur, DC; Desmond, R; Fay, MP; Holland-Thomas, N; Khoury, P; Klion, AD; Kurlander, R; Maric, I; Pabon, A; Ware, JM	1
Bernard, PL; Cinq-Mars, A; Cloutier, S; Dubois, M; Larose, É; Leblanc, MH; Sénéchal, M	1
Ai, XF; Fang, LW; Hu, NB; Li, B; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y	1
Bron, D; Cordier, JF; Cottin, V; Heimann, P; Lambert, F; Roufosse, F; Sidon, P	1
Heerema, NA; Kaffenberger, BH; Klisovic, R; Saultz, JN; Taylor, M	1
Darmanin, S; Fujioka, Y; Hashimoto, D; Hatakeyama, S; Ibata, M; Iwasaki, J; Kondo, T; Nakagawa, K; Ohba, Y; Onozawa, M; Teshima, T	1
Choi, CU; Kim, EJ; Lee, S; Na, JO	1
Cross, NC; Reiter, A	1
Ault, P; Cortes, J; Keating, M; Lynn, A; Verstovsek, S	1
Chen, SJ; Chen, Z; Fu, JF; Hu, J; Jin, J; Li, JM; Pan, Q; Shi, JY; Wang, LN; Zhao, WL	1
Cogan, E; Roufosse, F	2
Cross, NC; Erben, P; Fabarius, A; Grimwade, D; Haferlach, C; Hehlmann, R; Hochhaus, A; Metzgeroth, G; Popp, H; Reiter, A; Schmitt-Graeff, A; Schnittger, S; Walz, C	1
Alimena, G; Breccia, M; Cannella, L; Cilloni, D; Fama, A; Saglio, G; Santopietro, M; Stefanizzi, C; Tafuri, A	1
Cortes, J; Garcia-Manero, G; Jain, N; Kantarjian, H; Luthra, R; Manshouri, T; Quintás-Cardama, A; Verstovsek, S	1
Bosch, X; Garcia-Albeniz, X; Garcia-Alvarez, A; Loma-Osorio, P; Sionis, A; Sitges, M	1
Chu, ZB; Guo, T; He, J; Hu, Y; Sun, CY	1
Brzeźniakiewicz, K; Całbecka, M; Gajkowska, J; Helbig, G; Krzemień, S; Moskwa, A; Pogrzeba, J; Swiderska, A; Urbanowicz, A; Zdziarska, B	1
Butterfield, JH	1
Fermeglia, M; Greco, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Sandri, M; Tamborini, E; Virdis, E	1
Kobayashi, M; Kubota, T; Taguchi, H; Uemura, Y	1
de Revel, T; Fagot, T; Konopacki, J; Malfuson, JV; Mangouka, L; Souleau, B	1
Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S	1
Gleich, GJ; Leiferman, KM	2
Cutter, B; Gleich, GJ; Speckart, S; Wagner, LA	1
Bremerich, J; Winter, L; Zellweger, MJ	1
Doi, T; Fujimi, A; Huang, Y; Ishizu, A; Iwasaki, S; Kanisawa, Y; Ohta, H; Okuda, T; Sato, Y; Tanaka, S	1
Cancelas, JA; Rothenberg, ME; Yamada, Y	1
Kakakios, A; Kemp, A; Kilham, H; Mehr, S; Rego, S	1
Całbecka, M; Gajkowska, J; Hałasz, M; Helbig, G; Hus, M; Krzemień, S; Markiewicz, M; Moskwa, A; Piszcz, J; Seferyńska, I; Swiderska, A; Urbanowicz, A; Woszczyk, D	1
Acerboni, S; Barbui, T; Bassan, R; Carobbio, A; Delaini, F; Di Bona, E; Guerini, V; Intermesoli, T; Mappa, S; Paratore, S; Rambaldi, A; Rossi, G; Rossi, V; Salmoiraghi, S; Spinelli, O; Vannucchi, AM	1
Cools, J; Lierman, E	1
Di, YW; Liu, YH; Zhuang, HG	1
Bochner, BS; Butterfield, JH; Gleich, GJ; Huss-Marp, J; Kahn, JE; Klion, AD; Leiferman, KM; Nutman, TB; Ogbogu, PU; Pfab, F; Ring, J; Rothenberg, ME; Roufosse, F; Sajous, MH; Sheikh, J; Simon, D; Simon, HU; Stein, ML; Wardlaw, A; Weller, PF	1
Bosi, A; Pieri, L; Vannucchi, AM	1
Gałazka, K; Majewski, M; Rodzaj, M; Zduńczyk, A	1
Gotlib, J; Pardanani, A; Tefferi, A	1
Broussolle, C; Charhon, A; Dufour, JF; Green, L; Kahn, JE; Le Scanff, J; Sève, P	1
Hutyra, M; Kozák, J; Lukl, J; Szotkowski, T; Táborský, M; Václavík, J	1
Ikezoe, T; Nishioka, C; Tasaka, T; Togitani, K; Yokoyama, A	1
Haba, Y; Hanzawa, K; Itoyama, S; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Saito, Y; Sekiguchi, Y; Tamaru, J; Tokuhira, M; Tomikawa, A; Watanabe, R	1
Asou, H; Iwato, K; Kimura, A; Tanaka, H	1
Schwartz, LB; Sheikh, J; Singh, A	1
Dengler, TJ; Hardt, SE; Katus, HA; Lossnitzer, D; Perz, JB; Volz, HC; Weiss, C; Zankl, AR	1
Brisou, P; Cournac, JM; de Jaureguiberry, JP; Martinaud, C; Ménard, G; Pons, S; Souraud, JB	1
Matsui, T; Sada, A	1
Antoniu, SA	2
Barker, B; Moudgil, H; Slocombe, G; Srinivasan, K	1
Gau, JP; Hsiao, LT; Liu, CY; Pai, JT; Teng, HW; Tzeng, CH; Wang, JR; Yen, CC	1
Li, Q; Li, Z; Lu, Q; Tse, W; Yang, R; Yuan, R; Zhao, J	1
D'Orazio, J; Pulliam, J	1
Cioch, M; Dmoszynska, A; Helbig, G; Hus, M; Kata, D; Kozinska, J; Kyrcz-Krzemien, S; Morawska, M; Szczepanska-Szerej, H; Wieczorek, P; Woźniak, M	1
Berdel, WE; Cross, NC; Elling, C; Erben, P; Frickenhaus, M; Hochhaus, A; Hofmann, WK; Koschmieder, S; Müller-Tidow, C; Reiter, A; Schemionek, M; Serve, H; Stehling, M; Walz, C	1
Dudziński, M; Hałasz, M; Helbig, G; Hus, M; Kyrcz-Krzemień, S; Soja, A; Stachowicz, M; Więcławek, A	1
Burbury, K; Catalano, A; Chew, LP; Seymour, JF; Westerman, D	1
Całbecka, M; Helbig, G; Hus, M; Kyrcz-Krzemień, S; Moskwa, A; Piszcz, J; Raźny, M; Rodzaj, M; Seferyńska, I; Swiderska, A; Urbanowicz, A; Żuk, E	1
Hoffman, R; Kiladjian, JJ; Mesa, RA	1
Backlund, B; Cianciolo, RE; Clubb, FJ; Cook, AK; Lees, GE	1
Arnautovic-Custovic, A; Hasic, S; Jahic, A; Jovic, S; Kopic, E	1
Lavanya, R; Sankar, J; Srinivasan, A	1
Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C	1
Harada, H; Harada, Y; Imagawa, J; Kimura, A; Matsumoto, K; Morita, K; Tarutani, M; Yoshida, T	1
Awano, N; Kitamura, S; Ryu, T; Takazoe, M; Tanaka, M; Yoshimura, N	1
Chatziantoniou, V; Kotsopoulou, M; Maltezas, D; Mitsouli-Mentzikof, C; Papanikolaou, X; Triantafillopoulou, ID; Zoi, A	1
Anastasiadis, A; Christoforidou, A; Douvali, E; Kotsianidis, I; Margaritis, D; Tsatalas, C	1
Abouzahir, A; Amezyane, T; Badaoui, M; El Khattabi, A; Elomri, N; Elqatni, M; Fatihi, J; Ghafir, D; Hammi, S; Jira, M; Mekouar, F; Sekkach, Y; Smaali, J	1
Herrmann, H; Ramos Leal, N; Salamon, J; Schumacher, U; Thamer, M; Ullrich, S; Valent, P; Wicklein, D	1
Butterfield, JH; Weiler, CR	1
Chen, Z; Deng, X; Duan, C; He, D; Li, B; Li, C; Li, R; Li, X; Lu, J; Tang, F; Tang, Y; Zhang, C; Zhang, G	1
Harn, L; Najera, JE	1
Arefi, M; Briz, MM; de Arriba, F; García, JL; Gutiérrez, NC; Hernández-Rivas, JM; López, J; Martín-Núñez, G; Martínez, J; Merino, MA; Moreno, MJ; Rodríguez, JN; Suárez, JG	1
Aktan, C; Dalmızrak, A; Inalpolat, E; Kaymaz, BT; Kosova, B; Okan, V; Pehlivan, M; Sahin, HH; Saydam, G; Selvi, N; Yılmaz, M	1
D'Angelo, P; Farruggia, P; Giugliano, E; Lorenzatti, R; Russo, D; Santoro, A; Trizzino, A	1
Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C	1
Baxter, EJ; Cross, NC; Li, CY; Pardanani, A; Porrata, LF; Reeder, T; Tazelaar, HD; Tefferi, A; Witzig, TE	1
Ault, P; Cortes, J; Ferrajoli, A; Kaled, ES; Kantarjian, H; Koller, C; Letvak, L; Rios, MB; Thomas, D; Wierda, W	1
Schwartz, RS	1
Alam, R; Boogaerts, M; Clark, J; Cools, J; Cortes, J; Coutre, SE; Cross, NC; DeAngelo, DJ; Galinsky, I; Gilliland, DG; Gotlib, J; Griffin, JD; Kantarjian, H; Kutok, J; Legare, RD; Malone, J; Marynen, P; Rose, M; Schmid, J; Schrier, SL; Stone, R; Stover, EH; Tefferi, A; Vandenberghe, P; Verhoef, G; Wlodarska, I	1
Akin, C; Cools, J; Gilliland, DG; Klion, AD; Law, MA; Metcalfe, DD; Noel, P; Nutman, TB	1
Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J	1
Cogan, E; Goldman, M; Roufosse, FE	1
Brockman, SR; Cools, J; Cross, NC; Dewald, GW; Flynn, HC; Gilliland, DG; Ketterling, RP; Li, CY; Pardanani, A; Paternoster, SF; Reeder, TL; Shearer, BM; Tefferi, A	1
Bain, BJ	2
Grossi, O; Planchon, B; Pottier, P	1
Friedrich, MJ	1
Akin, C; Brown, M; Dunbar, C; Klion, AD; Law, M; Metcalfe, DD; Noel, P; Nutman, TB; Robyn, J	1
Amata, C; Arrigo, C; Azzarello, D; Coglitore, S; La Gattuta, G; Pitini, V; Righi, M	1
Koury, MJ; Murray, JJ; Newman, JH	1
Cools, J; Drexler, HG; Gilliland, DG; Griffin, JD; Huntly, BJ; Marynen, P; Quentmeier, H	1
Abboud, M; Bazarbachi, A; Bitar, N; Chami, B; Chehal, A; Kadri, A; Salem, Z; Zalloua, PA	1
Bourgeois, E; Cambier, N; Dupire, S; Grardel, N; Preudhomme, C; Roche-Lestienne, C; Rose, C	1
Coutré, S; Gotlib, J	2
Boogaerts, M; Cools, J; Gilliland, DG; Hagemeijer, A; Herregods, MC; Maerevoet, M; Marynen, P; Michaux, L; Roufosse, F; Selleslag, D; Van Hoof, A; Vandenberghe, P; Vanstraelen, D; Verhoef, G; Wlodarska, I; Zachée, P	1
Bauer, H; Frickhofen, N; Hochhaus, A; Jung, B; Märker-Hermann, E; Reiter, A; Walz, C	1
Bain, B	1
Baccarani, M; Malagola, M; Martinelli, G; Ottaviani, E; Rosti, G; Trabacchi, E	1
Pardanani, A; Tefferi, A	1
Ishii, Y; Ito, Y; Kuriyama, Y; Ohyashiki, K; Tauchi, T	1
Cools, J; Coutré, SE; Gilliland, DG; Gotlib, J; Malone, JM; Schrier, SL	1
Hamza, S; Jacobson, E; Skelton, H; Smith, KJ	1
Carella, AM; Catalano, G; Coco, FL; Minervini, MM; Musto, P; Perla, G	1
Gilliland, DG; Klion, AD; Stone, RM	1
Cools, J; Gilliland, G; Marynen, P; Stover, EH; Wlodarska, I	1
Goh, YT; Hwang, W; Ng, HJ; Tan, D; Tan, P	1
Baccarani, M; Malagola, M; Martinelli, G; Ottaviani, E; Piccaluga, PP; Ricci, P; Rondoni, M; Visani, G	1
Accadia, M; Ascione, L; De Michele, M; Rumolo, S; Spadaro, P; Tuccillo, B	1
Bisceglia, M; Bodenizza, C; Carella, AM; Cascavilla, N; Dell'Olio, M; Falcone, A; La Sala, A; Mantuano, S; Melillo, L; Minervini, MM; Musto, P; Nobile, M; Perla, G; Sanpaolo, G; Scalzulli, PR	1
Abakumov, EM; Domracheva, EV; Khoroshko, ND; Nemchenko, IS; Semenova, EA; Sokolova, MA; Turkina, AG; Vinogradova, OIu; Zakharova, AV	1
Gastl, G; Rumpold, H; Wolf, D	1
McArthur, GA; Seshadri, T; Seymour, JF	1
Arthur, D; Choksi, M; Dunbar, C; Klion, A; Noel, P; Nutman, T; O'neal, P; Robyn, J; Wlodarska, I	1
Catalano, L; D'Errico, A; Di Francia, R; Frigeri, F; Galderisi, M; Guerriero, A; La Starza, R; Luciano, L; Mecucci, C; Pinto, A; Pollio, G; Rotoli, B	1
Barete, S; Blanchet, O; Bletry, O; Cambier, N; Demarty, AL; Dib, M; Drupt, F; Fenaux, P; Gardembas, M; Hachulla, E; Hatron, PY; Kahn, JE; Laï, JL; Lepers, S; Libersa, C; Maloum, K; Philippe, N; Preudhomme, C; Prin, L; Quesnel, B; Roche-Lestienne, C; Rose, C; Roumier, AS; Soenen-Cornu, V	1
Jones, RL; Judson, IR	1
Al Aly, Z; Gellens, ME; González, EA; Philoctête Ashley, JM	1
Dai, CW; Li, B; Pei, MF; Zhang, GS	1
Jacob, S; Kovacs, RJ	1
Assa'ad, AH; Rothenberg, ME; Sutton, SA	1
Rappaport, E; Szymanski, J	1
Fukushima-Nakase, Y; Harada, H; Imashuku, S; Kakazu, N; Kuroda, H; Morimoto, A; Tamura, S; Teramura, T; Ueda, I	1
Borbényi, Z	1
Eckhardt, S	1
Cools, J	2
Aventin, A; Beacci, D; Cuneo, A; Foppoli, M; Invernizzi, R; La Starza, R; Luciano, L; Martelli, MF; Marynen, P; Mecucci, C; Nozzoli, C; Sambani, C; Specchia, G; Testoni, N	1
Brzezinska-Kolarz, B; Musial, J; Sanak, M; Szczeklik, A	1
Carulli, G; Cervetti, G; Galimberti, S; Petrini, M	1
Khoroshko, ND; Kokhno, AV; Nemchenko, IS; Semenova, EA; Sokolova, MA; Turkina, AG; Zakharova, AV	1
Bruckner-Tuderman, L; Hofmann, SC; Lübbert, M; Martens, UM; Mertelsmann, R; Müller, AM	1
Kio, EA; Lazarchick, J; Onitilo, AA; Singh, AK	1
Gherlinzoni, F; Gottardi, M; Manzato, E	1
Arrigo, C; Cavallari, V; Pitini, V; Sturniolo, G	1
Binder, T; Esterbauer, H; Florian, S; Haas, OA; Müllauer, L; Sillaber, C; Sperr, WR; Valent, P	1
Helbig, G; Hołowiecki, J; Stella-Hołowiecka, B	1
Cross, NC; Curtis, C; Grand, FH; Jotterand, M; Score, J; Stalder, M; Waghorn, K	1
Fujita, H; Kurata, M; Maeda, A; Matsui, T; Matsushita, A; Nagai, K; Sada, A; Takahashi, T; Tanaka, Y; Togami, K; Watanabe, N	1
Robyn, J	1
Bober, G; Grosicki, S; Helbig, G; Hochhaus, A; Holowiecki, J; Krawczyk, M; Reiter, A; Stella-Holowiecka, B; Wojnar, J	1
Cogan, E; Goldman, M; Roufosse, F	1
Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P	1
Pardanani, A; Patnaik, MM; Tefferi, A	1
Cortes, J; Giles, FJ; Huynh, L; Kantarjian, H; Manley, P; Manshouri, T; Quintás-Cardama, A; Tefferi, A; Verstovsek, S	1
Duyster, J; Gorantla, SP; Peschel, C; Thöne, S; von Bubnoff, N	1
de Vries, RA; Mattijssen, V; van der Heijden, AJ; van der Reijden, BA; Verstappen, MC; Wahab, PJ	1
Bruijnzeel-Koomen, CA; Lokhorst, HM; van Ruth, S	1
Gotoh, M; Kawasugi, K; Noguchi, M; Shirafuji, N; Shirasaki, R; Tashiro, H	1
Cross, NC; Curtis, C; Erben, P; Haferlach, T; Hehlmann, R; Hochhaus, A; Lengfelder, E; Metzgeroth, G; Müller, MC; Reiter, A; Schnittger, S; Schoch, C; Schultheis, B; Walz, C	1
Cowen, EW; Klion, AD; McBurney, E; McPherson, T	1
Altavilla, G; Arrigo, C; Naro, C; Pitini, V; Righi, M	1
Cools, J; de Ruiter, GS; Leeksma, OC; Terpstra, WE; van der Hulst, VP; Vandenberghe, P	1
Bruckner-Tuderman, L; Hofmann, SC; Lübbert, M; Müller, AM; Technau, K	1
Bain, B; Fletcher, S	1
Amariglio, N; Ashur-Fabian, O; Ellis, MH; Trakhtenbrot, L	1
Beacci, D; Chase, A; Cools, J; Crescenzi, B; Cross, NC; Gallì, A; Jones, AV; Martelli, MF; Marynen, P; Mecucci, C; Rosti, V; Specchia, G; Starza, RL; Vandenberghe, P	1
Aggarwal, S; Duggal, L; Garg, A; Jain, N	1
Apperley, J; Brito-Babapulle, F; Cilloni, D; Cross, NC; Erben, P; Gottardi, E; Grimwade, D; Hehlmann, R; Hochhaus, A; Jovanovic, JV; Martinelli, G; Metzgeroth, G; Ottaviani, E; Popp, H; Preudhomme, C; Reiter, A; Roche-Lestienne, C; Rondoni, M; Saglio, G; Score, J; Solomon, E; Waghorn, K; Walz, C	1
Gawaz, M; Schreiber, K; Zuern, CS	1
Burkland, GA; Langhoff, PJ; Schaller, JL	1
Buitenhuis, M; Coffer, PJ; Cools, J; Verhagen, LP	1
Shinkarow, JW	1
Grzybowski, G; Mikołajczyk, K; Samborski, W; Walkowiak, B; Zaba, R	1
Cortes, J; Giles, FJ; Kantarjian, H; Lamb, P; Manshouri, T; Pan, J; Quintás-Cardama, A; Tefferi, A; Verstovsek, S	1
Ma, ES; Siu, LL; Wong, CL; Wong, KF	1
How, GF; Ng, HJ; Tan, DC; Yiu, RC	1
Armentano, A; Bisconte, MG; Gentile, C; Gentile, M; Lucia, E; Martinelli, G; Mazzone, C; Morabito, F; Ottaviani, E; Rondoni, M; Vigna, E	1
Clark, A; Cross, NC; Curtis, CE; Grand, FH; Minervini, MM; Murphy, J; Musto, P; Perla, G; Reiter, A; Stewart, J	1
Benezet-Mazuecos, J; de la Fuente, A; Farre, J; Marcos-Alberca, P	1
Kalac, M; Kantarjian, H; Quintás-Cardama, A; Verstovsek, S; Vrhovac, R	1
García, M; Mauri, M; Ramila, E; Reynaga, E	1
Astolfi, C; Baccarani, M; Buccisano, F; Cilloni, D; de Vivo, A; Giugliano, E; Gottardi, E; Iacobucci, I; Martinelli, G; Merante, S; Messa, F; Ottaviani, E; Pane, F; Paolini, S; Rancati, F; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N; Tiribelli, M	1
Albano, F; Anelli, L; La Starza, R; Liso, V; Lonoce, A; Rocchi, M; Specchia, G; Zagaria, A	1
Dunbar, CE; Fay, MP; Fu, W; Hartsell, M; Klion, AD; Law, MA; Lemery, S; Maric, I; Noel, P; Nutman, TB; Robyn, J; Schmid, L; Talar-Williams, C	1
Gross, WL; Hellmich, B; Holl-Ulrich, K	1
Cools, J; Simon, HU	1
Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G	1
Peros-Golubicić, T; Smojver-Jezek, S	1
Chen, MH; Chen, MT; Chou, CW; Hsu, SP; Lee, LS; Lin, CF; Shih, YH	1
Arai, A; Hayashi, S; Inazawa, J; Miura, O; Wakabayashi, S; Yan, W	1
Dahabreh, IJ; Giannouli, S; Moutsopoulos, HM; Voulgarelis, M; Zoi, C; Zoi, K	1
Ben Romdhane, N; Hafsia, R; Menif, S	1
Hiraizumi, K; Hirasawa, N; Hong, J; Ishihara, K; Kaneko, M; Kitamura, H; Ohuchi, K; Seyama, T; Takahashi, A; Zee, O	1
Doi, T; Fujimi, A; Kanisawa, Y; Kikuchi, S; Nobuoka, A; Ohta, H; Okuda, T; Sato, Y; Umeda, I	1
Salemi, S; Simon, D; Simon, HU; Yousefi, S	1
Bown, N; Kalra, S; Nath, U; Neylon, AJ; Wilkins, BS; Williams, C; Wilson, V	1
Larsen, H; Sørensen, AL	1
Całbecka, M; Gajkowska, J; Grzegorczyk, J; Helbig, G; Hołowiecki, J; Klimkiewicz, R; Lewandowska, M; Majewski, M; Moskwa, A; Stella-Hołowiecka, B	1
Binder, T; Jäger, U; Krauth, MT; Ohler, L; Valent, P	1
Burkland, GA; Schaller, JL	1
Butterfield, JH; Gleich, GJ; Leiferman, KM; Pardanani, A; Tefferi, A	1

Reviews

53 review(s) available for imatinib mesylate and Endocarditis, Loeffler

Article	Year
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:8 Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male	2022
Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). Expert review of hematology, 2019, Volume: 12, Issue:12 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Imidazoles; Interferon-alpha; Precision Medicine; Pyridazines	2019
Cough in hypereosinophilic syndrome: case report and literature review. BMC pulmonary medicine, 2020, Apr-15, Volume: 20, Issue:1 Topics: Adult; Cough; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2020
[Acute myeloid leukemia with FIP1L1-PDGFRA fusion gene treated with imatinib: a case report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020, 12-14, Volume: 41, Issue:12 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2020
Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis. British journal of haematology, 2021, Volume: 195, Issue:5 Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Cyclosporine; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Interleukin-5; Lymphocyte Activation; Lymphocytes	2021
Imatinib for the treatment of hypereosinophilic syndromes. Expert review of clinical immunology, 2018, Volume: 14, Issue:2 Topics: Animals; Antineoplastic Agents; Eosinophils; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction	2018
[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:2 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2013
PDGF receptor signaling networks in normal and cancer cells. Cytokine & growth factor reviews, 2014, Volume: 25, Issue:3 Topics: Benzamides; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infections; Leukemia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stroke	2014
Eosinophilia in mast cell disease. Immunology and allergy clinics of North America, 2014, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Cell Communication; Eosinophils; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Stem Cell Factor	2014
How I treat hypereosinophilic syndromes. Blood, 2015, Aug-27, Volume: 126, Issue:9 Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Drug Discovery; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Protein Kinase Inhibitors	2015
Eosinophilia in Hematologic Disorders. Immunology and allergy clinics of North America, 2015, Volume: 35, Issue:3 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Leukemia, Myelomonocytic, Chronic; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2015
Management of Hypereosinophilic Syndromes. Immunology and allergy clinics of North America, 2015, Volume: 35, Issue:3 Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia; mRNA Cleavage and Polyadenylation Factors; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha	2015
[The Hypereosinophilic Syndromes in Childhood]. Klinische Padiatrie, 2015, Volume: 227, Issue:6-7 Topics: Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Cytostatic Agents; Diagnosis, Differential; Drug Approval; Germany; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Infant; Interleukin-5; Protein-Tyrosine Kinases; Rare Diseases	2015
[Treatment of adult acute lymphoblastie leukemia with eosinophilia and abnormality of PDGFRA by autologous hematopoietic stem cell transplantation and imatinib: one case report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:10 Topics: Adult; Eosinophilia; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor alpha	2015
Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta haematologica, 2008, Volume: 119, Issue:4 Topics: Animals; Benzamides; Chromosomes, Human; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2008
The hypereosinophilic syndromes: current concepts and treatments. British journal of haematology, 2009, Volume: 145, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clone Cells; Female; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes	2009
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia. International archives of allergy and immunology, 2009, Volume: 149 Suppl 1 Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction	2009
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert review of anticancer therapy, 2009, Volume: 9, Issue:9 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Delivery Systems; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2009
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clinic proceedings, 2010, Volume: 85, Issue:2 Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor	2010
Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Current medical research and opinion, 2010, Volume: 26, Issue:8 Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
[Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Reference Standards	2010
Novel therapies for hypereosinophilic syndromes. The Netherlands journal of medicine, 2010, Volume: 68, Issue:1 Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bone Marrow Transplantation; CD52 Antigen; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib	2010
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood, 2011, May-05, Volume: 117, Issue:18 Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential	2011
Treatment of hypereosinophilic syndromes--the first 100 years. Seminars in hematology, 2012, Volume: 49, Issue:2 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antiviral Agents; Benzamides; CD52 Antigen; Glycoproteins; History, 20th Century; History, 21st Century; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Interleukin-5; Piperazines; Polyethylene Glycols; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins	2012
Clinical management of the hypereosinophilic syndromes. Expert review of hematology, 2012, Volume: 5, Issue:3 Topics: Adrenal Cortex Hormones; Antibodies; Benzamides; Enzyme Inhibitors; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2012
FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature. Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:1 Topics: Adolescent; Age of Onset; Antineoplastic Agents; Benzamides; Bone Marrow; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2014
Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. British journal of haematology, 2003, Volume: 122, Issue:2 Topics: Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Enzyme Inhibitors; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Translocation, Genetic	2003
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 2004, Volume: 14, Issue:1 Topics: Animals; Benzamides; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Substrate Specificity	2004
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Benzamides; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2004
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood, 2004, Apr-15, Volume: 103, Issue:8 Topics: Algorithms; Antineoplastic Agents; Benzamides; Cytogenetics; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes	2004
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Benzamides; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Monomeric GTP-Binding Proteins; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2004
FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis, Systemic; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oncogenes; Piperazines; Pyrimidines; Radiation Chimera; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays	2004
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 2004, Volume: 14, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. American journal of hematology, 2004, Volume: 77, Issue:1 Topics: Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2004
The development and application of imatinib. Expert opinion on drug safety, 2005, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2005
Anti-IL-5 and hypereosinophilic syndromes. Clinical immunology (Orlando, Fla.), 2005, Volume: 115, Issue:1 Topics: Adult; Antibodies, Monoclonal; Benzamides; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2005
Hypereosinophilic syndrome: two case reports of contrasting variants. Southern medical journal, 2005, Volume: 98, Issue:4 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2005
[Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Decision Trees; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2005
[Clinical studies with imatinib in 2004]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2005
FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 2005, Volume: 67, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2005
The hypereosinophilic syndromes: still more heterogeneity. Current opinion in immunology, 2005, Volume: 17, Issue:6 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mast Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2005
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]. Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 113, Issue:5 Topics: Algorithms; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chronic Disease; Dose-Response Relationship, Drug; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2005
Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Seminars in respiratory and critical care medicine, 2006, Volume: 27, Issue:2 Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; CD52 Antigen; Glucocorticoids; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interleukin-5; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
Eosinophilia: secondary, clonal and idiopathic. British journal of haematology, 2006, Volume: 133, Issue:5 Topics: Benzamides; Bone Marrow; Chromosome Aberrations; Cytokines; Eosinophilia; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pulmonary Eosinophilia; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2006
Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:5 Suppl Topics: Aged; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Pemphigoid, Bullous; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2007
Imatinib mesylate for the treatment of hypereosinophilic syndromes. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:11 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2006
Diagnosis and treatment of hypereosinophilic syndromes. Current opinion in hematology, 2007, Volume: 14, Issue:1 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2007
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer, 2007, Sep-01, Volume: 110, Issue:5 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Clone Cells; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2007
[Hypereosinophilic syndrome--recent developments in diagnosis and treatment]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:37 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Immunosuppressive Agents; Interferon-alpha; Lung Diseases; Neoplasms; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Necrosis Factor-alpha; Vasculitis	2007
Novel approaches to therapy of hypereosinophilic syndromes. Immunology and allergy clinics of North America, 2007, Volume: 27, Issue:3 Topics: Antibodies, Monoclonal; Benzamides; Bone Marrow Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2007
Imatinib mesylate in the treatment of hematologic malignancies. Expert opinion on biological therapy, 2007, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome	2007
Hypereosinophilic syndrome: diagnosis and treatment. Current opinion in pulmonary medicine, 2007, Volume: 13, Issue:5 Topics: Antibodies, Monoclonal; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Eosinophilia; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2007
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosomes, Human, Pair 4; Chronic Disease; Exons; Female; Furosemide; Glucocorticoids; Heart Diseases; Heart Ventricles; Hepatocytes; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Introns; Liver Diseases; Lymphocytes; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Necrosis; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Deletion; Sodium Potassium Chloride Symporter Inhibitors; Thrombosis	2007

Trials

8 trial(s) available for imatinib mesylate and Endocarditis, Loeffler

Article	Year
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. British journal of haematology, 2008, Volume: 143, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Neoplasm, Residual; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2008
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. British journal of haematology, 2009, Volume: 147, Issue:5 Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Eosinophils; Female; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2009
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 2003, Jun-15, Volume: 101, Issue:12 Topics: Adult; Aged; Benzamides; Bone Marrow; Cardiovascular Diseases; Enzyme Inhibitors; Eosinophils; Female; Fusion Proteins, bcr-abl; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Nervous System Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Skin Diseases	2003
Effective treatment of hypereosinophilic syndrome with imatinib mesylate. The hematology journal : the official journal of the European Haematology Association, 2003, Volume: 4, Issue:6 Topics: Adult; Base Sequence; Benzamides; Child; Chromosomes, Human, Pair 8; DNA Primers; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotyping; Leukocyte Count; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Trisomy	2003
Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. International journal of hematology, 2006, Volume: 83, Issue:5 Topics: Adult; Asian People; Benzamides; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 4; Chronic Disease; Enzyme Activation; Eosinophilia; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic	2006
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood, 2007, Nov-15, Volume: 110, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biopsy; Chronic Disease; Dose-Response Relationship, Drug; Drug Dosage Calculations; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction; Withholding Treatment	2007
Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine, 2007, Volume: 86, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetic Analysis; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Patient Selection; Piperazines; Prednisone; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Translocation, Genetic	2007
A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. British journal of haematology, 2008, Volume: 141, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome	2008

Other Studies

189 other study(ies) available for imatinib mesylate and Endocarditis, Loeffler

Article	Year
Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm. Leukemia research, 2022, Volume: 121 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Polycythemia; Stem Cells	2022
Hematological hypereosinophilia Annales de biologie clinique, 2022, 07-01, Volume: 80, Issue:4 Topics: Female; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies	2022
Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome. Clinical and experimental dermatology, 2023, Mar-22, Volume: 48, Issue:4 Topics: Aged; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2023
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases. The Journal of dermatology, 2023, Volume: 50, Issue:10 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphomatoid Papulosis; Male; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factors	2023
Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies. The journal of allergy and clinical immunology. In practice, 2023, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Biological Factors; Biological Products; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate	2023
FIP1L1::PDGFRA fusion driving three synchronous haematological malignancies. Pathology, 2023, Volume: 55, Issue:7 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factors	2023
[Complete remission of Loeffler's endocarditis with Imatinib in a myeloid and lymphoid neoplasm associated with eosinophilia]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:1 Topics: Antineoplastic Agents; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Male; Middle Aged	2020
Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group. Polish archives of internal medicine, 2020, 03-27, Volume: 130, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Poland; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2020
[Hypereosinophilic syndromes]. La Revue du praticien, 2019, Volume: 69, Issue:7 Topics: Eosinophils; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate	2019
Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Lymphomatoid Papulosis; Male; Middle Aged; Protein Kinase Inhibitors; Skin Neoplasms; Treatment Outcome	2020
Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Leukemia & lymphoma, 2020, Volume: 61, Issue:9 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukoencephalopathy, Progressive Multifocal; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2020
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction. Annals of hematology, 2020, Volume: 99, Issue:7 Topics: Adult; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mutation; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Translocation, Genetic	2020
S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells. Frontiers in immunology, 2020, Volume: 11 Topics: Animals; Apoptosis; Calgranulin A; Calgranulin B; Cell Line, Tumor; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mice; Mitochondria; Models, Biological; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Proteins	2020
FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction. Stroke, 2021, Volume: 52, Issue:10 Topics: Adult; Brain; Cerebral Infarction; Coronary Thrombosis; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ischemic Stroke; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retrospective Studies; Treatment Outcome	2021
Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure. The Canadian journal of cardiology, 2017, Volume: 33, Issue:5 Topics: Adult; Anticoagulants; Antineoplastic Agents; Bone Marrow Examination; Echocardiography; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Prednisone; Receptor, Platelet-Derived Growth Factor alpha; Thrombosis; Treatment Outcome; Warfarin	2017
Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. Acta dermato-venereologica, 2017, Jul-06, Volume: 97, Issue:7 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphomatoid Papulosis; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Skin Neoplasms; Treatment Outcome	2017
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. The Korean journal of internal medicine, 2018, Volume: 33, Issue:3 Topics: Adult; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea	2018
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. Medicine, 2017, Volume: 96, Issue:36 Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma, T-Cell; Male; Oncogene Proteins, Fusion	2017
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Blood Cell Count; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein	2018
[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2018, Jun-14, Volume: 39, Issue:6 Topics: Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2018
Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia. The Canadian journal of cardiology, 2018, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Biopsy; Disease Progression; Endocardium; Endomyocardial Fibrosis; Heart Failure; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Myocardium; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome	2018
Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation. The Journal of dermatology, 2019, Volume: 46, Issue:6 Topics: Diagnosis, Differential; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mouth Mucosa; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Pemphigus; Receptor, Platelet-Derived Growth Factor alpha; Severity of Illness Index; Stomatitis; Treatment Outcome	2019
Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis. BMJ case reports, 2019, Apr-29, Volume: 12, Issue:4 Topics: Adrenal Cortex Hormones; Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Bone Diseases; Child, Preschool; Drug Combinations; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ivermectin; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Rare Diseases; Receptor, Platelet-Derived Growth Factor alpha; Strongyloides stercoralis; Strongyloidiasis; Treatment Outcome	2019
Polyarthritis as the Initial Presentation of Hyper Eosinophilic Syndrome. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:6 Topics: Aged; Anti-Bacterial Agents; Arthritis; Arthritis, Infectious; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Prednisolone; Treatment Outcome	2019
Loeffler endocarditis in a pediatric patient. Pediatric hematology and oncology, 2014, Volume: 31, Issue:4 Topics: Antineoplastic Agents; Benzamides; Child, Preschool; Electrocardiography; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Pyrimidines	2014
Rapid left ventricular thickening and thrombus caused by FIP1L1/PDGFRA-negative hypereosinophilic syndrome. Texas Heart Institute journal, 2013, Volume: 40, Issue:3 Topics: Benzamides; Biopsy; Cerebral Infarction; Disease Progression; Echocardiography; Fibrosis; Genetic Predisposition to Disease; Hemodynamics; Humans; Hypereosinophilic Syndrome; Hypertrophy, Left Ventricular; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Phenotype; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Thrombosis; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left	2013
Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. American journal of hematology, 2014, Volume: 89, Issue:1 Topics: Antineoplastic Agents; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome; Withholding Treatment	2014
Isolated bilateral uveitis in child with hypereosinophilic syndrome. Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:7 Topics: Benzamides; Child; Female; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Uveitis; Vision Disorders	2014
Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dyspnea; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Muscle Weakness; Piperazines; Pyrimidines; Sweating	2014
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene. Leukemia & lymphoma, 2015, Volume: 56, Issue:3 Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia; Male; Middle Aged; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins; Translocation, Genetic	2015
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget, 2014, Jul-15, Volume: 5, Issue:13 Topics: Adolescent; Aged; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotype; Leukemia; Male; Middle Aged; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome	2014
[Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case]. Revista medica de Chile, 2014, Volume: 142, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome	2014
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget, 2014, Nov-15, Volume: 5, Issue:21 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Growth Processes; Drug Resistance; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Protein v-akt; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2014
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood cancer journal, 2015, Feb-06, Volume: 5 Topics: Benzamides; Eosinophilia; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tankyrases	2015
Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. JAMA dermatology, 2015, Volume: 151, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Histiocytosis, Non-Langerhans-Cell; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2015
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM. Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2015
Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome. Pediatric blood & cancer, 2016, Volume: 63, Issue:1 Topics: Child, Preschool; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA	2016
A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia. Cancer genetics, 2015, Volume: 208, Issue:10 Topics: Adult; Antineoplastic Agents; Cytogenetic Analysis; Forkhead Transcription Factors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins	2015
Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leukemia & lymphoma, 2016, Volume: 57, Issue:3 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Treatment Outcome	2016
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. Transplantation, 2015, Volume: 99, Issue:11 Topics: Adult; Antineoplastic Agents; Biopsy; Cardiomyopathies; Fibrosis; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Magnetic Resonance Imaging; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2015
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. Leukemia, 2016, Volume: 30, Issue:6 Topics: Aged; Antineoplastic Agents, Immunological; Chronic Disease; Delayed Diagnosis; DNA-Binding Proteins; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-sis	2016
Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα. BMJ case reports, 2016, Jan-12, Volume: 2016 Topics: Antineoplastic Agents; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oral Ulcer; Receptor, Platelet-Derived Growth Factor alpha	2016
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy, 2016, Volume: 71, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Bone Marrow; Eosinophils; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Phenotype; Prognosis; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2016
Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work? European journal of internal medicine, 2016, Volume: 32 Topics: Adult; Aged; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Young Adult	2016
Management of Loeffler's Endocarditis With Bivalvular Involvement and a FIP1L1/PDGFRA-Negative Mutation. The Canadian journal of cardiology, 2016, Volume: 32, Issue:12 Topics: Adult; Bioprosthesis; Echocardiography; Fibrosis; Genetic Testing; Heart Valve Prosthesis Implantation; Heart Ventricles; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging, Cine; Male; Mitral Valve; Mitral Valve Insufficiency; Papillary Muscles; Protein Kinase Inhibitors; Thrombosis; Treatment Outcome; Tricuspid Valve	2016
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; China; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia; Maintenance Chemotherapy; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Time Factors; Treatment Outcome; Young Adult	2016
Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association. Respiration; international review of thoracic diseases, 2016, Volume: 91, Issue:5 Topics: Aged; Antineoplastic Agents; Chronic Disease; Cough; Delayed Diagnosis; Diagnosis, Differential; DNA-Binding Proteins; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia; Lung; Male; mRNA Cleavage and Polyadenylation Factors; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed; Transcription Factors	2016
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. JAMA dermatology, 2016, 12-01, Volume: 152, Issue:12 Topics: Adult; Biopsy; Chromosomes, Human, Pair 5; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Receptor, Platelet-Derived Growth Factor beta; Skin	2016
Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Cancer science, 2017, Volume: 108, Issue:2 Topics: Apoptosis; Cell Nucleus; HEK293 Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Inhibitors of Activated STAT; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; STAT1 Transcription Factor; Sumoylation; Transfection	2017
Regression of biventricular Loeffler's endocarditis after early treatment. European heart journal. Cardiovascular Imaging, 2017, May-01, Volume: 18, Issue:5 Topics: Adult; Aphasia; Cerebral Infarction; Early Diagnosis; Echocardiography; Follow-Up Studies; Headache; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Risk Assessment; Secondary Prevention; Treatment Outcome; Warfarin	2017
Pregnancy in a patient with hypereosinophilic syndrome. Leukemia research, 2009, Volume: 33, Issue:1 Topics: Adult; Benzamides; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Pregnancy; Pregnancy Complications, Hematologic; Pyrimidines	2009
FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chinese medical journal, 2008, May-20, Volume: 121, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; fms-Like Tyrosine Kinase 3; Genotype; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2008
[Practical approach to hypereosinophilia]. Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4 Topics: Benzamides; Eosinophils; Food Hypersensitivity; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Mutation; Neoplasms; Parasitic Diseases; Piperazines; Prednisone; Protein-Tyrosine Kinases; Pulmonary Eosinophilia; Pyrimidines	2008
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6 Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Patient Compliance; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction	2009
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. International journal of cardiology, 2010, Mar-04, Volume: 139, Issue:2 Topics: Benzamides; Biopsy; Cardiotoxins; Echocardiography; Female; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thrombosis; Ventricular Dysfunction, Left	2010
Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate. International journal of hematology, 2009, Volume: 89, Issue:1 Topics: Adult; Benzamides; Gene Rearrangement; Heart Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. British journal of haematology, 2009, Volume: 145, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Young Adult	2009
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leukemia research, 2009, Volume: 33, Issue:8 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Proteins; Time Factors	2009
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. Journal of the National Cancer Institute, 2009, Feb-04, Volume: 101, Issue:3 Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Research Design; Threonine	2009
A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Respirology (Carlton, Vic.), 2009, Volume: 14, Issue:2 Topics: Adult; Benzamides; Chronic Disease; Cough; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2009
[Hematological disorders and hypereosinophilias]. La Revue de medecine interne, 2009, Volume: 30, Issue:4 Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Gene Rearrangement; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2009
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy, 2009, Volume: 64, Issue:6 Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib	2009
Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:6 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; CD52 Antigen; Female; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-gamma; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
[Endomyocardial fibrosis in chronic eosinophilic leukemia]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2009, Volume: 181, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Aberrations; Echocardiography; Endocardium; Endomyocardial Fibrosis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
[Spontaneous pneumothorax, an unusual manifestation of imatinib-resistant chronic eosinophilic leukemia: an autopsy study]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4 Topics: Aged; Antineoplastic Agents; Autopsy; Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pneumothorax; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5. The Journal of pediatrics, 2009, Volume: 155, Issue:2 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Child; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infusions, Intravenous; Interleukin-5; Leukocyte Count; Male; Piperazines; Prednisolone; Pyrimidines	2009
Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematological oncology, 2010, Volume: 28, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Cough; Female; Hepatomegaly; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Incidental Findings; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Platelet Count; Poland; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; RNA, Messenger; RNA, Neoplasm; Splenomegaly; Young Adult	2010
[Eosinophils and related diseases]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2009, Volume: 38, Issue:7 Topics: Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cell Differentiation; Cell Movement; Cell Survival; Eosinophilia; Eosinophils; Helminthiasis; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Piperazines; Pyrimidines	2009
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:6 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Chemokine CCL17; Child; Cyclosporine; Drug Therapy, Combination; Eosinophils; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Interleukin-5; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Tryptases; Young Adult	2009
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. Annals of hematology, 2010, Volume: 89, Issue:7 Topics: Animals; Antineoplastic Agents; Benzamides; Echocardiography; Electrocardiography; Eosinophils; Female; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Middle Aged; Piperazines; Pyrimidines; Troponin	2010
A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. Polskie Archiwum Medycyny Wewnetrznej, 2009, Volume: 119, Issue:12 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
[Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome]. La Revue de medecine interne, 2010, Volume: 31, Issue:4 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Serositis	2010
Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. American journal of hematology, 2010, Volume: 85, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Benzamides; Drug Therapy, Combination; Endocarditis; Eosinophils; Heart; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prednisone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Thrombosis; Treatment Outcome; Warfarin	2010
Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Treatment Outcome	2010
[Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:5 Topics: Acute Kidney Injury; Aged, 80 and over; Benzamides; Disseminated Intravascular Coagulation; Drug Synergism; Fatal Outcome; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Eosinophilic, Acute; Methylprednisolone; Piperazines; Pleural Effusion; Pulse Therapy, Drug; Pyrimidines; Tumor Lysis Syndrome	2010
Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:12 Topics: Adult; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Red-Cell Aplasia, Pure	2010
Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. International journal of cardiology, 2011, Sep-15, Volume: 151, Issue:3 Topics: Adult; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Hypertrophy, Left Ventricular; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2011
[Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome]. La Revue de medecine interne, 2011, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Gene Rearrangement, T-Lymphocyte; Genetic Testing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes; Treatment Outcome	2011
Persistent cough: an unusual cause. Idiopathic hypereosinophilic syndrome (HES). Thorax, 2010, Volume: 65, Issue:11 Topics: Benzamides; Chronic Disease; Cough; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed	2010
A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:6 Topics: Adult; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Eosinophilia; Eosinophils; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Myeloproliferative Disorders; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2010
Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. Pediatric blood & cancer, 2011, Volume: 56, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Child; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 5; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Translocation, Genetic; Treatment Outcome; Tropomyosin	2011
Hypereosinophilic syndrome presenting as acute myocardial infarction in an adolescent. The Journal of pediatrics, 2011, Volume: 158, Issue:4 Topics: Adolescent; Benzamides; Cerebral Infarction; Drug Therapy, Combination; Electrocardiography; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Myocardial Infarction; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2011
Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib. Leukemia research, 2011, Volume: 35, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Quadriplegia; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2011
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood, 2011, Mar-10, Volume: 117, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Separation; Cell Transformation, Neoplastic; Female; Flow Cytometry; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mice; Piperazines; Point Mutation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays	2011
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult	2012
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leukemia & lymphoma, 2011, Volume: 52, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Lineage; Chronic Disease; Clone Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, T-Cell; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2011
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Retrospective Studies; Splenomegaly; Time Factors; Young Adult	2011
Minimal change glomerulopathy in a cat. Journal of feline medicine and surgery, 2011, Volume: 13, Issue:4 Topics: Animals; Benzamides; Cat Diseases; Cats; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Nephrosis, Lipoid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2011
Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form. Medicinski arhiv, 2011, Volume: 65, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines	2011
Steroid-unresponsive hypereosinophilic syndrome. Annals of tropical paediatrics, 2011, Volume: 31, Issue:3 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Drug Therapy, Combination; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Prednisolone; Pyrimidines; Steroids; Treatment Outcome	2011
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia, 2012, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib	2012
[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7 Topics: Aged; Benzamides; Chronic Disease; Dasatinib; Drug Monitoring; Drug Tolerance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Thiazoles; Treatment Outcome	2011
Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:16 Topics: Benzamides; Chronic Disease; Colitis, Ulcerative; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Young Adult	2011
An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report. Annals of hematology, 2012, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Erythroid Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed	2012
Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. American journal of hematology, 2012, Volume: 87, Issue:1 Topics: Aged; Benzamides; Bone Marrow Cells; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphocytes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, alpha-beta; Remission Induction; Treatment Outcome	2012
[Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy]. Annales pharmaceutiques francaises, 2011, Volume: 69, Issue:5 Topics: Adult; Asthma; Benzamides; Electrocardiography; Eosinophils; Female; Humans; Hypereosinophilic Syndrome; Hypertension; Hypertension, Pulmonary; Imatinib Mesylate; Leukocyte Count; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protease Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2011
Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PloS one, 2012, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Models, Animal; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mice; Mice, SCID; Neoplasm Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Heterologous	2012
Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. PloS one, 2012, Volume: 7, Issue:4 Topics: Benzamides; Down-Regulation; Enzyme Activation; Eosinophils; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Janus Kinase 2; mRNA Cleavage and Polyadenylation Factors; NF-kappa B; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; STAT3 Transcription Factor; STAT5 Transcription Factor; Tumor Cells, Cultured; Tyrphostins	2012
Chronic eosinophilic leukemia presenting with mouth and penile ulcers. The American journal of medicine, 2012, Volume: 125, Issue:8 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Examination; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 4; Diagnosis, Differential; Eosinophils; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oral Ulcer; Penile Diseases; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Ulcer	2012
Response to imatinib mesylate in patients with hypereosinophilic syndrome. International journal of hematology, 2012, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotype; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2012
Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment. Molecular biology reports, 2013, Volume: 40, Issue:2 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Molecular Diagnostic Techniques; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Polymorphism, Restriction Fragment Length; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2013
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia research, 2002, Volume: 26, Issue:9 Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy	2002
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Adult; Benzamides; Drug Evaluation; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Treatment Outcome; Ventricular Dysfunction, Left	2003
The hypereosinophilic syndrome and the biology of cancer. The New England journal of medicine, 2003, Mar-27, Volume: 348, Issue:13 Topics: Benzamides; Chromosome Deletion; Enzyme Inhibitors; Eosinophilia; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Translocation, Genetic	2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England journal of medicine, 2003, Mar-27, Volume: 348, Issue:13 Topics: Adult; Base Sequence; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Enzyme Inhibitors; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombination, Genetic; Remission Induction	2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood, 2003, Jun-15, Volume: 101, Issue:12 Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Base Sequence; Benzamides; Biopsy; Bone Marrow; Chromosomes, Human, Pair 4; Endomyocardial Fibrosis; Eosinophils; Female; Fibrosis; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocytes, Mononuclear; Lung Diseases; Male; Mast Cells; Mastocytosis; Middle Aged; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA; Serine Endopeptidases; Splenomegaly; Tryptases; Vitamin B 12	2003
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2003, Jun-24, Volume: 100, Issue:13 Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine	2003
Hypereosinophilic syndrome. The New England journal of medicine, 2003, Jun-26, Volume: 348, Issue:26 Topics: Benzamides; Chromosome Deletion; Clone Cells; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Phenotype; Piperazines; Pyrimidines; Recombination, Genetic; T-Lymphocytes	2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, Nov-01, Volume: 102, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Eosinophilia; Gene Rearrangement; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Predictive Value of Tests; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Treatment Outcome	2003
[Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]. La Revue de medecine interne, 2003, Volume: 24, Issue:8 Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Male; Piperazines; Pyrimidines; Treatment Outcome	2003
From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism. Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15 Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Adult; Antigens, CD; Benzamides; Bone Marrow; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Patient Selection; Piperazines; Primary Myelofibrosis; Pyrimidines; Receptors, Interleukin-2	2004
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood, 2003, Nov-01, Volume: 102, Issue:9 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Treatment Outcome; Troponin T	2003
Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. The American journal of medicine, 2003, Volume: 115, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Drug Therapy, Combination; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Lymphomatoid Papulosis; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2003
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 2004, Apr-01, Volume: 103, Issue:7 Topics: Apoptosis; Base Sequence; Benzamides; Biomarkers; Blotting, Western; Cell Division; Cell Line, Tumor; DNA Primers; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Models, Biological; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins	2004
Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia, 2004, Volume: 18, Issue:2 Topics: Adult; Benzamides; Cord Blood Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous	2004
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia, 2004, Volume: 18, Issue:4 Topics: Adult; Benzamides; Chromosomes, Human, Pair 4; Clone Cells; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate	2004
Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Adult; Antineoplastic Agents; Arm; Azathioprine; Benzamides; Brain; Cerebellar Ataxia; Cerebellar Cortex; Enzyme Inhibitors; Headache; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Memory Disorders; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Paresis; Parietal Lobe; Piperazines; Polyarteritis Nodosa; Prednisone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Vertigo	2004
The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica, 2004, Volume: 89, Issue:2 Topics: Benzamides; Clone Cells; Cytokines; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Models, Biological; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; T-Lymphocyte Subsets	2004
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica, 2004, Volume: 89, Issue:2 Topics: Aged; Benzamides; Enzyme Inhibitors; Exons; HL-60 Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; RNA Splicing; RNA, Messenger	2004
Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Adult; Benzamides; Growth Substances; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Piperazines; Primary Myelofibrosis; Pyrimidines; Treatment Outcome	2004
Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. Archives of dermatology, 2004, Volume: 140, Issue:5 Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Genetic Testing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines	2004
Imatinib-mesylate for all patients with hypereosinophilic syndrome? Leukemia research, 2004, Volume: 28, Issue:7 Topics: Benzamides; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Genetic Heterogeneity; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic	2004
Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. International journal of hematology, 2004, Volume: 80, Issue:1 Topics: Adult; Benzamides; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. Haematologica, 2004, Volume: 89, Issue:8 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2004
Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2004, Volume: 5, Issue:5 Topics: Adult; Benzamides; Diagnosis, Differential; Echocardiography, Doppler; Electrocardiography; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2004
Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leukemia & lymphoma, 2004, Volume: 45, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; T-Lymphocytes; Treatment Outcome	2004
[Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome]. Terapevticheskii arkhiv, 2004, Volume: 76, Issue:7 Topics: Adult; Benzamides; Eosinophils; Fusion Proteins, bcr-abl; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Treatment Outcome	2004
[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Deutsche medizinische Wochenschrift (1946), 2004, Oct-01, Volume: 129, Issue:40 Topics: Benzamides; Enzyme Inhibitors; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Vasculitis, Central Nervous System	2004
Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. The New England journal of medicine, 2004, Nov-11, Volume: 351, Issue:20 Topics: Adolescent; Benzamides; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Oligospermia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Imatinib-responsive hypereosinophilia in a patient with B cell ALL. Leukemia & lymphoma, 2004, Volume: 45, Issue:12 Topics: Adult; Benzamides; Burkitt Lymphoma; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Piperazines; Pyrimidines	2004
Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leukemia & lymphoma, 2004, Volume: 45, Issue:12 Topics: Adult; Benzamides; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; mRNA Cleavage and Polyadenylation Factors; Neoplasm Staging; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Ultrasonography	2004
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 2005, Volume: 19, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Cytogenetic Analysis; Exons; Female; France; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interleukin-5; Male; Middle Aged; Molecular Sequence Data; Piperazines; Pyrimidines; Sequence Analysis, DNA; Serine Endopeptidases; Tryptases	2005
Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:4 Topics: Acute Kidney Injury; Adult; Benzamides; Combined Modality Therapy; Female; Fever of Unknown Origin; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Lymphatic Diseases; Piperazines; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Pyrimidines; Renal Dialysis; Retinal Artery Occlusion	2005
[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib]. Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7 Topics: Adult; Benzamides; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Janus Kinase 1; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction	2005
Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate. Clinical cardiology, 2005, Volume: 28, Issue:4 Topics: Adult; Benzamides; Echocardiography; Eosinophils; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Myocardial Contraction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thrombosis	2005
Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations. International journal of hematology, 2005, Volume: 81, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Treatment Outcome	2005
The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica, 2005, Volume: 90, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets	2005
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica, 2005, Volume: 90, Issue:5 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Benzamides; Bone Marrow Cells; Child; Chromosome Deletion; Chromosomes, Human, Pair 4; Drug Therapy, Combination; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Organ Specificity; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Analysis	2005
Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. European journal of haematology, 2005, Volume: 75, Issue:1 Topics: Adult; Antineoplastic Agents; Atrial Function, Left; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines	2005
Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. Leukemia research, 2005, Volume: 29, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction	2005
[FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. Terapevticheskii arkhiv, 2005, Volume: 77, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; DNA, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotyping; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2005
Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Annals of hematology, 2006, Volume: 85, Issue:1 Topics: Adult; Aged; Benzamides; Chromosomes, Human, Pair 4; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction	2006
Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leukemia & lymphoma, 2005, Volume: 46, Issue:11 Topics: Aortic Valve Insufficiency; Benzamides; Cardiomegaly; Chromosomes, Human, Pair 8; Cytogenetic Analysis; Heart Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Mitral Valve Insufficiency; Piperazines; Pyrimidines; Remission Induction; Trisomy	2005
Imatinib and hyperlipidemia. The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2005
Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. British journal of haematology, 2006, Volume: 132, Issue:2 Topics: Adult; Benzamides; Female; Gastroenteritis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed	2006
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leukemia research, 2006, Volume: 30, Issue:9 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiomyopathies; Eosinophil Cationic Protein; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Serine Endopeptidases; Tryptases; World Health Organization	2006
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia, 2006, Volume: 20, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genetic Testing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Oncogene Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome	2006
Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. International journal of hematology, 2006, Volume: 83, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma, Non-Hodgkin; Male; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA	2006
Imatinib-responsive hypereosinophilic syndrome. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Benzamides; Dose-Response Relationship, Drug; Eosinophilia; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome	2006
The results of imatinib therapy for patients with primary eosinophilic disorders. European journal of haematology, 2006, Volume: 76, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Evaluation; Eosinophilia; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; K562 Cells; Kidney Neoplasms; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib	2006
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leukemia research, 2006, Volume: 30, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood, 2006, Jun-15, Volume: 107, Issue:12 Topics: Amino Acid Substitution; Benzamides; Cells, Cultured; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
[A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Nederlands tijdschrift voor geneeskunde, 2006, May-27, Volume: 150, Issue:21 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oral Ulcer; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
[Two patients with hypereosinophilic syndrome]. Nederlands tijdschrift voor geneeskunde, 2006, May-27, Volume: 150, Issue:21 Topics: Adult; Benzamides; Diagnosis, Differential; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prednisone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stem Cell Transplantation	2006
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes, chromosomes & cancer, 2006, Volume: 45, Issue:10 Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Cell Cycle Proteins; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 9; Chronic Disease; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Nerve Tissue Proteins; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2006
Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. The British journal of dermatology, 2006, Volume: 155, Issue:4 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphomatoid Papulosis; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? Leukemia research, 2007, Volume: 31, Issue:5 Topics: Apoptosis; Benzamides; Biomarkers; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2007
[A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia]. Nederlands tijdschrift voor geneeskunde, 2006, Sep-02, Volume: 150, Issue:35 Topics: Adult; Anticoagulants; Antineoplastic Agents; Benzamides; Gene Expression Regulation, Neoplastic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome	2006
A clonal hypereosinophilic syndrome with specific and effective therapy: a report of two cases. The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:12 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers; Diagnosis, Differential; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Prednisone; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Outcome	2006
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia, 2007, Volume: 21, Issue:3 Topics: AC133 Antigen; Antigens, CD; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Lineage; Chronic Disease; Clone Cells; Drug Resistance; Eosinophils; Erythrocytes; Fusion Proteins, bcr-abl; Glycophorins; Glycoproteins; Granulocytes; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Megakaryocytes; Monocytes; mRNA Cleavage and Polyadenylation Factors; Myeloid Cells; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tumor Stem Cell Assay; X Chromosome Inactivation	2007
Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Adult; Benzamides; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2006
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 2007, Jun-01, Volume: 109, Issue:11 Topics: Antineoplastic Agents; Benzamides; Chronic Disease; DNA Primers; Exons; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Kinetics; mRNA Cleavage and Polyadenylation Factors; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Time Factors; Treatment Outcome; United Kingdom	2007
Loeffler endocarditis: findings on magnetic resonance imaging. Heart (British Cardiac Society), 2007, Volume: 93, Issue:3 Topics: Aged, 80 and over; Benzamides; Cardiomyopathies; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Angiography; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2007
Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia. MedGenMed : Medscape general medicine, 2007, Feb-27, Volume: 9, Issue:1 Topics: Animals; Babesia; Babesiosis; Benzamides; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Species Specificity	2007
Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Benzamides; Cell Differentiation; Cell Growth Processes; Chronic Disease; Enzyme Activation; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; mRNA Cleavage and Polyadenylation Factors; Myeloid Cells; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; STAT5 Transcription Factor	2007
Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate". MedGenMed : Medscape general medicine, 2007, Volume: 9, Issue:1 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines	2007
[The hypereosinophilic syndrome: case report]. Annales Academiae Medicae Stetinensis, 2006, Volume: 52 Suppl 2 Topics: Adult; Benzamides; Bone Marrow; Diagnosis, Differential; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferons; Lymphatic Diseases; Male; Methylprednisolone; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Treatment Outcome	2006
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia, 2007, Volume: 21, Issue:7 Topics: Apoptosis; Benzamides; Caspase 3; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tumor Cells, Cultured	2007
Detection of FIP1L1-PDGFRA fusion by FISH. British journal of haematology, 2007, Volume: 138, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Gene Deletion; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction	2007
Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. Leukemia research, 2008, Volume: 32, Issue:1 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction	2008
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Orbital Neoplasms; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Tomography, X-Ray Computed	2008
Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. British journal of haematology, 2007, Volume: 138, Issue:1 Topics: Antineoplastic Agents; Benzamides; Calmodulin-Binding Proteins; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; ETS Translocation Variant 6 Protein; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Membrane Proteins; Middle Aged; Nerve Tissue Proteins; Oncogene Fusion; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic	2007
Loeffler endocarditis: what have we learned? American journal of hematology, 2007, Volume: 82, Issue:10 Topics: Benzamides; Cardiovascular Agents; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Models, Biological; Piperazines; Pyrimidines	2007
[Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy]. Medicina clinica, 2007, Jun-23, Volume: 129, Issue:4 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, Volume: 92, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2007
Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Chronic Disease; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic	2008
Idiopathic hypereosinophilic syndrome with infiltration of cerebrospinal fluid by immature eosinophils: a case report and literature review. Surgical neurology, 2007, Volume: 68 Suppl 1 Topics: Aged; Antineoplastic Agents; Benzamides; Cerebrospinal Fluid Shunts; Eosinophils; Fatal Outcome; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Intracranial Hypertension; Male; Piperazines; Prognosis; Pyrimidines; Subdural Effusion; Subdural Space; Tomography, X-Ray Computed; Treatment Failure	2007
[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. La Revue de medecine interne, 2008, Volume: 29, Issue:1 Topics: Adult; Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2008
Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. Biochemical and biophysical research communications, 2008, Feb-22, Volume: 366, Issue:4 Topics: Benzamides; Butadienes; Cell Differentiation; Cell Line; Cell Proliferation; Hypereosinophilic Syndrome; Imatinib Mesylate; Mitogen-Activated Protein Kinases; mRNA Cleavage and Polyadenylation Factors; Nitriles; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, CCR3	2008
[Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Dec-10, Volume: 96, Issue:12 Topics: Aged; Benzamides; Clone Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes	2007
Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:4 Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Base Sequence; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins	2008
FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Journal of clinical pathology, 2008, Volume: 61, Issue:5 Topics: Benzamides; Brain Diseases; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2008
[Treatment of idiopathic hypereosinophilic syndrome with imatinib]. Ugeskrift for laeger, 2008, Jan-21, Volume: 170, Issue:4 Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2008
Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. Leukemia research, 2008, Volume: 32, Issue:11 Topics: Adult; Antineoplastic Agents; Benzamides; Heart Failure; Humans; Hypereosinophilic Syndrome; Hypertension, Pulmonary; Imatinib Mesylate; Male; Mitral Valve Insufficiency; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2008
Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed : Medscape general medicine, 2001, Sep-07, Volume: 3, Issue:5 Topics: Adult; Benzamides; Drug Therapy, Combination; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Male; Piperazines; Pyrimidines	2001
Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (London, England), 2002, May-04, Volume: 359, Issue:9317 Topics: Administration, Oral; Adult; Benzamides; Enzyme Inhibitors; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome	2002